Research Update

Adam Green, MD | Assistant Professor of Pediatrics | Attending Physician in Pediatric Neuro-Oncology/Oncology

We recently received an update from Adam Green, MD | Assistant Professor of Pediatrics at the University of Colorado School of Medicine and Attending, Physician, in Pediatric Neuro-Oncology/Oncology at Children’s Hospital Colorado on the research that TeamConnor funded in 2013 with a $50,000 grant. We originally funded his research at Dana-Farber Cancer Institute at Boston Children’s Hospital, and he then transitioned the research when he joined the Children’s Hospital in Colorado. We applaud Dr. Green with this research and the findings of his research in the published publication.

I wanted to let you know about the attached paper we published this month on research that was partially funded by our TeamConnor Community Impact grant, which is acknowledged in the paper. Selinexor, a novel cancer drug that works by inhibiting a protein that exports tumor suppressor proteins (the brakes in cells) from the nucleus where they function, was recently FDA approved for an adult cancer called multiple myeloma and is in clinical trials for other cancers including high-grade glioma (HGG), a leading cause of cancer death in children. We studied patient-derived cell lines and mouse models to understand how Selinexor works in HGG. We found that Selinexor decreases tumor proliferation and increases cell death by increasing the expression of another protein called NGFR that blocks activation of an important cancer pathway called NF-kB. This mechanism of action suggests potential combination therapies, including proteasome inhibition, that may work with Selinexor against HGG, which we begin to investigate here. The first pediatric clinical trial of Selinexor in childhood brain and solid tumors, which I am leading, is still open nationally. This work will help us determine which patients may benefit most from this medicine and how to combine it with other chemotherapy medicines to make it more effective.

Click download to read the article.

You can leave a response, or trackback from your own site.

Leave a Comment

You must be logged in to post a comment.

Our Featured Hero

Ashley Piltz

Ashley Piltz

Our world completely changed on September 12, 2007..

Read More
TeamConnor

Did You Know

Building awareness of childhood cancer is critical to funding and finding a cure. To help, please consider sharing teamconnor.org on your Facebook.

Today, 46 children will be diagnosed with cancer.  Seven will lose their battle.

Did you know September is National Childhood Cancer Awareness Month!

Every day in America, approximately 46 children are diagnosed with cancer.

Childhood cancer does not discriminate, sparing no ethnic group, socio-economic class, or geographic region.

Rhabdomyosarcoma is the most common soft tissue sarcoma in children, accounting for about 3% of childhood cancers.

On average, 1 in every 4 elementary schools has a child with cancer.

About one-third of childhood cancers are leukemias.

Childhood cancer survival rates in the United States have increased from less than 20% in the 1960s to almost 80% today.

Cancer kills more children each year than Asthma, Cystic Fibrosis, Diabetes, and Pediatric AIDS combined.

Childhood cancer is not one disease entity, but rather a spectrum of different malignancies. Cancers found in children are biologically different from those seen in adults.

1 in 300 children will develop cancer before age 20.

Neuroblastoma is the most common extra cranial solid tumor cancer in children.

Today, up to 75% of the children with cancer can be cured, yet, some forms of childhood cancers have proven so resistant to treatment that, in spite of research, a cure is illusive.

Sign up to comment in the forums, on posts, and receive our newsletters.

Your Email Address
Sign Up
TeamConnor